Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing neffy, a needle-free intranasal epinephrine spray for emergency treatment of Type I allergic reactions, including anaphylaxis. With a significant market opportunity of approximately $3 billion in the U.S., ARS targets 20 million patients at risk of severe allergies. The company is innovating with direct-to-consumer marketing and expanding regulatory approvals globally, aiming to transform epinephrine delivery.
This description was generated via AI from an annual report. Updated about 1 year ago.